Skip to main content

PTN

Stock
Health Care
Biotechnology

Performance overview

PTN Price
Price Chart

Forward-looking statistics

Beta
1.13
Risk
96.44%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.

Company info

SectorHealth Care
IndustryBiotechnology
Employees39
Market cap$30.2M

Fundamentals

Enterprise value-$611.7K
Revenue$350.0K
Revenue per employee
Profit margin97.83%
Debt to equity-0.06

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$1.54
Dividend per share
Revenue per share$0.02
Avg trading volume (30 day)$34K
Avg trading volume (10 day)$25K
Put-call ratio

Macro factor sensitivity

Growth-4.0
Credit+7.4
Liquidity+1.3
Inflation-5.0
Commodities-2.2
Interest Rates-2.0

Valuation

Dividend yield0.00%
PEG Ratio0.05
Price to sales6.99
P/E Ratio0.05
Enterprise Value to Revenue-1.75
Price to book-0.66

Upcoming events

Next earnings dayNovember 14, 2024
Next dividend day
Ex. dividend day

News

C&S Wholesale To Acquire SpartanNash In Bid To Take On Grocery Giants

Byron Center, Michigan-based SpartanNash Co. plans to sell its business to a privately-held wholesale grocery distributor, and the parent company of Piggly Wiggly Supermarkets, in a $1.77 billion deal, the companies announced this morning.

Forbes (June 23, 2025)
Cramer's Mad Dash: Spartan Nash Co.

Jim Cramer breaks down why he's keeping an eye on shares of Spartan Nash Co.

CNBC Television (June 23, 2025)
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?

Palatin Technologies (PTN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (May 20, 2024)
Palatin Technologies Stock Moves Higher After Outlining Plans For Dry Eye Disease Treatment

Palatin Technologies Inc (NYSE: PTN) has completed an End-of-Phase 2 (EOP2) meeting with the FDA for PL9643 for the treatment of dry eye disease (DED). Palatin remains on track to initiate the Phase 3 program in DED patients during Q4 of 2021, with data readout expected in 2H of 2022.

Benzinga (June 29, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free